stockrowCardiff Oncology, Inc.
CRDF Healthcare Biotechnology
Cardiff Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $593,000.00, down 13.2% from fiscal 2024.
- Revenue
- −14.1%
- EPS
- +33.3%
- Free cash flow
- −41.4%
Quarter to June 2026, against a year earlier
Follow CRDF
Alert me
Cardiff Oncology, Inc. (CRDF) Beneish M-score
Cardiff Oncology, Inc.'s Beneish M-score for fiscal 2025 is −4.02; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −4.02 | (2.13) |
| FY2024 | −1.89 | 1.80 |
| FY2023 | −3.69 | (1.55) |
| FY2022 | −2.13 | (1.07) |
| FY2021 | −1.06 | 1.12 |
| FY2020 | −2.19 | (1.21) |
| FY2019 | −0.97 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.27 | — | 0.25 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 1.49 | — | 0.60 | |
| Sales growth index | 0.87 | — | 0.77 | |
| Depreciation index Depreciation not reported — index set to 1 | 1.00 | — | Set to 1 | 0.12 |
| SG&A index | 1.31 | — | −0.23 | |
| Total accruals to total assets | (0.13) | — | −0.60 | |
| Leverage index | 1.92 | — | −0.63 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −4.02 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| XBIT XBiotech Inc. compare | −4.2× |
| CRDF Cardiff Oncology, Inc. | −4.0× |
| SPRO Spero Therapeutics, Inc. compare | −1.0× |
| FBIO Fortress Biotech, Inc. compare | 0.0× |
| GOSS Gossamer Bio, Inc. compare | 0.7× |
| CGTX Cognition Therapeutics, Inc. compare | — |
| CLNN Clene Inc. compare | — |
| TELO Telomir Pharmaceuticals, Inc. compare | — |
| TENX Tenax Therapeutics, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI